Explore 3 Stock Ideas & Industry Insights Download Free Report
The Scotts Miracle-Gro Company

SMG Details
The Scotts Miracle-Gro Company (NYSE: SMG) is among the world’s most prominent brands of branded consumer products for lawn and garden care. It has the industry’s most recognized brands, and its Scotts®, Miracle-Gro® and Ortho® brands are market-leading in their categories.

Result Performance for the First Quarter Ended 1 January 2022 – (Q1FY22)

Source: Company Reports, Analysis by Kalkine Group
Key Updates
Outlook
The company has guided achieving company-wide sales growth of 0-3% in FY22 with the U.S. Consumer segment sales is expected to remain between 2 to negative 2%. While it forecasts Hawthorne sales to grow by around 8-12%, maximum growth is anticipated in the second half of the year. Moreover, the non-GAAP adjusted EPS is likely to stay in a range of $8.50-$8.90 and the gross margin is expected to decline by around 100 to 150 basis points. Besides, the company highlighted that it intends to repurchase up to another $300 million in shares during FY22 in addition to the $113 million of share repurchases undertaken in FY21.
Key Risks
The prevailing COVID-19 pandemic could adversely impact its business, results of operation, financial condition, and/or cash flows. Further, it is exposed to the risk of changes in regulations or regulatory enforcement priorities that could lead to an increase in its costs or restrict its ability to market all its products. It is also prone to climate change and unfavorable weather conditions that could adversely affect its financial results.
Valuation Methodology: EV/EBITDA Based Relative Valuation (Illustrative)

Technical Overview
Daily Price Chart

Source: REFINITIV, Note: Purple color line reflects Relative Strength Index (14-Period)

Stock Recommendation
The company has delivered a 6-month and one-year return of ~-19.33% and ~-44.48%, respectively. The stock is trading lower than the average price of the 52-week low-high range at $130.91–$254.34, respectively.
The stock has been valued using EV/EBITDA multiple based relative valuation (on an illustrative basis). The target price so arrived reflects a rise of low double-digit (in % terms). A slight premium has been applied to peer average EV/EBITDA multiple (NTM basis), considering a decent outlook for FY22 and its intention to take an inorganic route for growth.
Considering the factors above, we give a “Buy” recommendation on the stock at the closing market price of US$131.31 per share, down by 1.17% as of 7th February 2022.
The Scotts Miracle-Gro Company (SMG) is a part of Kalkine’s Global Big Money Product
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decisions should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the analysis has been achieved and subject to the factors discussed above alongside support levels provided.
Technical Indicators Defined:-
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices.
Disclaimer
The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.
Past performance is not a reliable indicator of future performance.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!